|
| 33960073 | Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B. | Haemophilia | 2021 |
| 33790846 | Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic Transformation. | Front Neurol | 2021 |
| 33540485 | Safety, pharmacokinetics, and pharmacodynamics of a next-generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients. | J Thromb Haemost | 2021 |
| 34430790 | Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety. | Res Pract Thromb Haemost | 2021 |
| 33112889 | Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa. | PLoS One | 2020 |
| 30450637 | Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. | Ann Neurol | 2019 |
| 30308028 | Oral carbon monoxide therapy in murine sickle cell disease: Beneficial effects on vaso-occlusion, inflammation and anemia. | PLoS One | 2018 |
| 28378932 | The role of carbon monoxide and heme oxygenase in the prevention of sickle cell disease vaso-occlusive crises. | Am J Hematol | 2017 |
| 27515331 | Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction. | J Am Coll Cardiol | 2016 |
| 27803392 | Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection. | Stroke | 2016 |
| 25609336 | Comparison of chromogenic and ELISA functional C1 inhibitor tests in diagnosing hereditary angioedema. | J Allergy Clin Immunol Pract | 2015 |
| 25803135 | Prevalence of hereditary angioedema in untested first-degree blood relatives of known subjects with hereditary angioedema. | Allergy Asthma Proc | 2015 |
| 23979365 | A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. | Crit Care Med | 2013 |
| 24372304 | Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers. | Curr Pharm Des | 2013 |
| 21455059 | Evaluation of MP4OX for prevention of perioperative hypotension in patients undergoing primary hip arthroplasty with spinal anesthesia: a randomized, double-blind, multicenter study. | Anesthesiology | 2011 |
| 21317165 | A double-blind, randomized, multicenter study of MP4OX for treatment of perioperative hypotension in patients undergoing primary hip arthroplasty under spinal anesthesia. | Anesth Analg | 2011 |
| 21341394 | CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS. | J Intensive Care Med | 2011 |
| 17350452 | Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. | Lancet | 2007 |
| 17895486 | Simplified pharmacoeconomics of critical care and severe sepsis. | J Intensive Care Med | 2007 |
| 17637378 | Gouty panniculitis in a healthy male. | J Am Acad Dermatol | 2007 |
| 17699383 | Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis. | Clin J Am Soc Nephrol | 2007 |
| 17253918 | Error rates among clinical pharmacists in calculating the APACHE II score. | Pharmacotherapy | 2007 |
| 16575354 | ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis. | Pediatr Crit Care Med | 2006 |
| 15632220 | Obesity does not alter the pharmacokinetics of drotrecogin alfa (activated) in severe sepsis. | Ann Pharmacother | 2005 |
| 16192478 | Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. | N Engl J Med | 2005 |
| 16277714 | Application of a population-based severity scoring system to individual patients results in frequent misclassification. | Crit Care | 2005 |
| 16277711 | Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated). | Crit Care | 2005 |
| 15891319 | Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. | Crit Care Med | 2005 |
| 14990780 | Comment: obese man treated with drotrecogin alfa (activated). | Ann Pharmacother | 2004 |
| 15640632 | Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. | Crit Care Med | 2004 |
| 15189943 | Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. | Chest | 2004 |
| 15494907 | Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. | Clin Infect Dis | 2004 |
| 14769742 | Transpyloric feeding tube placement in critically ill patients using electromyogram and erythromycin infusion. | Chest | 2004 |
| 12544987 | Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. | Crit Care Med | 2003 |
| 12939918 | The value of innovation. | S Afr Med J | 2003 |
| 14501959 | The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. | Crit Care Med | 2003 |
| 12582406 | Rickettsialpox in a patient with HIV infection. | J Am Acad Dermatol | 2003 |
| 12830408 | Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). | Clin Infect Dis | 2003 |
| 12794395 | Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. | Crit Care Med | 2003 |
| 12523456 | Erythromycin accelerates gastric emptying in a dose-response manner in healthy subjects. | Pharmacotherapy | 2003 |
| 11927905 | Treatment of severe tricyclic antidepressant overdose with extracorporeal sorbent detoxification. | Adv Ren Replace Ther | 2002 |
| 11398691 | Equal aspiration rates in gastrically and transpylorically fed critically ill patients. | Intensive Care Med | 2001 |
| 11310516 | Confirming the reliability of the sedation-agitation scale administered by ICU nurses without experience in its use. | Pharmacotherapy | 2001 |
| 11800089 | Treatment of systemic inflammatory response syndrome by push-pull powdered sorbent pheresis: a Phase 1 clinical trial. | Ther Apher | 2001 |
| 11588451 | Gastric feeding with erythromycin is equivalent to transpyloric feeding in the critically ill. | Crit Care Med | 2001 |
| 11703524 | Disseminated histoplasmosis presenting as pyoderma gangrenosum-like lesions in a patient with acquired immunodeficiency syndrome. | Int J Dermatol | 2001 |
| 11502657 | Hantavirus pulmonary syndrome due to Andes virus in Temuco, Chile: clinical experience with 16 adults. | Chest | 2001 |
| 10910024 | Push-pull sorbent-based pheresis and hemodiabsorption in the treatment of hepatic failure: preliminary results of a clinical trial with the BioLogic-DTPF System. | Ther Apher | 2000 |
| 11310904 | Trace element homeostasis during continuous sedation with propofol containing EDTA versus other sedatives in critically ill patients. | Intensive Care Med | 2000 |
| 11011786 | A multicenter, prospective study of the placement of transpyloric feeding tubes with assistance of a magnetic device. The Magnet-Guided Enteral Feeding Tube Study Group. | JPEN J Parenter Enteral Nutr | 2000 |